MX2015017780A - Composiciones y metodos para su uso en oncologia. - Google Patents
Composiciones y metodos para su uso en oncologia.Info
- Publication number
- MX2015017780A MX2015017780A MX2015017780A MX2015017780A MX2015017780A MX 2015017780 A MX2015017780 A MX 2015017780A MX 2015017780 A MX2015017780 A MX 2015017780A MX 2015017780 A MX2015017780 A MX 2015017780A MX 2015017780 A MX2015017780 A MX 2015017780A
- Authority
- MX
- Mexico
- Prior art keywords
- nanoparticles
- nanoparticle
- aggregate
- aggregates
- oncology
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0457—Semi-solid forms, ointments, gels, hydrogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para su uso en diagnóstico médico y en control de pacientes, normalmente en el contexto de terapia, en particular en el contexto de oncología para optimizar la irradiación local de un lecho tumoral. Más particularmente se refiere a un gel biocompatible que comprende nanopartículas y/o agregados de nanopartículas, en donde i) la densidad de cada nanopartícula y de cada agregado de nanopartículas es de al menos 7 g/cm3, comprendiendo la nanopartícula o agregados de nanopartículas un material inorgánico que comprende al menos un elemento de metálico que tiene un número atómico Z de al menos 25, más preferiblemente de al menos 40, estando cubierta cada una de dichas nanopartículas o de dichos agregados de nanopartículas con un recubrimiento biocompatible; ii) la concentración de nanopartículas y/o agregados de nanoparticulas es de al menos aproximadamente el 1% (p/p); y iii) la viscosidad aparente a 2 s-1 del gel que comprende las nanopartículas y/o agregados de nanopartículas, es entre aproximadamente 0.1 Pa.s y aproximadamente 1000 Pa.s cuando se mide entre 20° C y 37° C.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361837406P | 2013-06-20 | 2013-06-20 | |
| EP13305830 | 2013-06-20 | ||
| PCT/EP2014/062976 WO2014202738A1 (en) | 2013-06-20 | 2014-06-19 | Compositions and methods for use in oncology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015017780A true MX2015017780A (es) | 2016-07-06 |
Family
ID=48741003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015017780A MX2015017780A (es) | 2013-06-20 | 2014-06-19 | Composiciones y metodos para su uso en oncologia. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160136304A1 (es) |
| EP (1) | EP3010552B1 (es) |
| JP (1) | JP6484229B2 (es) |
| KR (1) | KR102217217B1 (es) |
| CN (1) | CN105431174B (es) |
| AU (1) | AU2014283232B2 (es) |
| BR (1) | BR112015031984A2 (es) |
| CA (1) | CA2915145C (es) |
| CY (1) | CY1121770T1 (es) |
| EA (1) | EA033792B1 (es) |
| HK (1) | HK1222561A1 (es) |
| MA (1) | MA38710A1 (es) |
| MX (1) | MX2015017780A (es) |
| PL (1) | PL3010552T3 (es) |
| RS (1) | RS58800B1 (es) |
| SG (1) | SG11201510468TA (es) |
| SI (1) | SI3010552T1 (es) |
| WO (1) | WO2014202738A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2857260C (en) | 2011-12-16 | 2019-10-15 | Nanobiotix | Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof |
| AU2014283217A1 (en) * | 2013-06-20 | 2015-12-24 | Nanobiotix | Compositions and methods for use in medical diagnosis |
| TW201705977A (zh) | 2015-05-28 | 2017-02-16 | 奈諾生技公司 | 作為治療疫苗之奈米顆粒 |
| US9607952B1 (en) * | 2015-10-30 | 2017-03-28 | International Business Machines Corporation | High-z oxide nanoparticles embedded in semiconductor package |
| CN113842395B (zh) * | 2021-10-15 | 2022-12-23 | 中国科学院高能物理研究所 | 钽纳米复合物及包含该钽纳米复合物的淋巴示踪剂、放疗增敏剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5370901A (en) * | 1991-02-15 | 1994-12-06 | Bracco International B.V. | Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients |
| FR2869803B1 (fr) * | 2004-05-10 | 2006-07-28 | Nanobiotix Sarl | Particules activables, preparation et utilisations |
| US20090304587A1 (en) | 2005-11-01 | 2009-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Biodegradable composite for internal local radiotherapy |
| US8043005B2 (en) * | 2006-06-02 | 2011-10-25 | Hydrapak, Inc. | Reservoir closure system and method |
| EP3583960A1 (en) * | 2009-12-15 | 2019-12-25 | Incept, LLC | Implants and biodegradable fiducial markers |
-
2014
- 2014-06-19 AU AU2014283232A patent/AU2014283232B2/en not_active Ceased
- 2014-06-19 CN CN201480035294.XA patent/CN105431174B/zh active Active
- 2014-06-19 MX MX2015017780A patent/MX2015017780A/es active IP Right Grant
- 2014-06-19 MA MA38710A patent/MA38710A1/fr unknown
- 2014-06-19 WO PCT/EP2014/062976 patent/WO2014202738A1/en active Application Filing
- 2014-06-19 KR KR1020167001665A patent/KR102217217B1/ko active IP Right Grant
- 2014-06-19 CA CA2915145A patent/CA2915145C/en active Active
- 2014-06-19 JP JP2016520500A patent/JP6484229B2/ja active Active
- 2014-06-19 SI SI201431195T patent/SI3010552T1/sl unknown
- 2014-06-19 RS RS20190657A patent/RS58800B1/sr unknown
- 2014-06-19 EP EP14731952.9A patent/EP3010552B1/en active Active
- 2014-06-19 BR BR112015031984A patent/BR112015031984A2/pt not_active IP Right Cessation
- 2014-06-19 SG SG11201510468TA patent/SG11201510468TA/en unknown
- 2014-06-19 US US14/898,767 patent/US20160136304A1/en not_active Abandoned
- 2014-06-19 EA EA201690042A patent/EA033792B1/ru not_active IP Right Cessation
- 2014-06-19 PL PL14731952T patent/PL3010552T3/pl unknown
-
2016
- 2016-09-12 HK HK16110779.8A patent/HK1222561A1/zh unknown
-
2019
- 2019-05-22 CY CY20191100546T patent/CY1121770T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3010552T1 (sl) | 2019-08-30 |
| AU2014283232A1 (en) | 2016-01-21 |
| KR20160027011A (ko) | 2016-03-09 |
| CA2915145C (en) | 2021-06-08 |
| BR112015031984A2 (pt) | 2017-07-25 |
| JP2016523244A (ja) | 2016-08-08 |
| EA201690042A1 (ru) | 2016-06-30 |
| SG11201510468TA (en) | 2016-01-28 |
| CN105431174B (zh) | 2019-06-07 |
| CY1121770T1 (el) | 2020-07-31 |
| PL3010552T3 (pl) | 2019-09-30 |
| CA2915145A1 (en) | 2014-12-24 |
| KR102217217B1 (ko) | 2021-02-18 |
| HK1222561A1 (zh) | 2017-07-07 |
| JP6484229B2 (ja) | 2019-03-13 |
| AU2014283232B2 (en) | 2019-03-28 |
| EA033792B1 (ru) | 2019-11-26 |
| EP3010552B1 (en) | 2019-04-17 |
| MA38710A1 (fr) | 2017-12-29 |
| RS58800B1 (sr) | 2019-07-31 |
| CN105431174A (zh) | 2016-03-23 |
| US20160136304A1 (en) | 2016-05-19 |
| WO2014202738A1 (en) | 2014-12-24 |
| EP3010552A1 (en) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
| MX2015017780A (es) | Composiciones y metodos para su uso en oncologia. | |
| ZA202110554B (en) | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors | |
| MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| UA109271C2 (uk) | Комбінація фітоканабіноїдів та темозоламіду для лікування гліоми | |
| MX2015017774A (es) | Composiciones y metodos para el uso en el diagnostico medico. | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| MX365801B (es) | Hidrogeles de poli(alquenilamida)-polisacárido para el tratamiento de formaciones subterráneas. | |
| NZ749217A (en) | Androgen receptor modulator and uses thereof | |
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| CR20120619A (es) | Métodos de tratamiento de cáncer de vejiga | |
| MX2015016155A (es) | Formulaciones en gel para dirigir la radioterapia. | |
| MX2012001716A (es) | Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf. | |
| MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
| MX2015001716A (es) | Niclosamida para el tratamiento de tumores solidos. | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| NZ703411A (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| MX2015009409A (es) | Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer. | |
| WO2013112643A8 (en) | Low density, highly porous nano structure | |
| BR112015026257A2 (pt) | terapia de combinação compreendendo um composto di-hidropirazino-pirazina e um antagonista do receptor de andrógeno para tratar câncer de próstata | |
| GB2543672A (en) | Anti-microbial foams containing polymer-stabilized silver nanoparticles | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| MX2023007706A (es) | Nanoparticulas para su uso como vacuna terapeutica. | |
| PT2948160T (pt) | Composições que contêm sulfato de condroitina, nattokinase e compostos de sulfidrilo para melhorar a biodisponibilidade de sulfato de condroitina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |